CM4620

DB16466InvestigationalSmall molecule

CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and NCT04661540 (critical...

Mechanism: CM4620 is a small molecule inhibitor of calcium release-activated channel. It inhibits calcium entry via the store-operated calcium entry channels (SOCE) and acts as an anti-inflammatory compound by reducing cytokine expression and myeloperoxidase activity.
Curator reviewed
Formula / weight: C₁₉H₁₁ClF₃N₃O₃ · 421.76 g/mol (avg)
Also known as: BENZAMIDE, N-(5-(6-CHLORO-2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)-2-PYRAZINYL)-2-FLUORO-6-METHYL- · N-(5-(6-CHLORO-2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)PYRAZIN-2-YL)-2-FLUORO-6-METHYLBENZAMIDE · ZEGOCRACTIN
Code names: AK549808 · BCP29536 · CM-4620 · CRAC inhibitor CM4620 · CS-0022201 · EX-A1898 · GTPL10087 · HY-101942 · orai1 inhibitor CM4620 · orai Ca2+ channel inhibitor CM4620 · SB18686

Resolves to

Compound

UNII564AW1RR37CAS1713240-67-5ChEMBLCHEMBL4753998

Structure

InChIKeyQQMKTHUGOQDEIL-UHFFFAOYSA-NSMILESCC1=CC=CC(F)=C1C(=O)NC1=NC=C(N=C1)C1=CC2=C(OC(F)(F)O2)C=C1Cl

Targets

Q13586STIM1Q96D31ORAI1

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with CM4620, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account